References
- DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
- Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294–297.
- Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
- Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. DOI:https://doi.org/10.1056/NEJMoa1910836.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with pd-l1 tumor proportion score ≥ 50%. J Clin Oncol. 2021;2339–2349.
- Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. DOI:https://doi.org/10.1056/NEJMoa2002788.
- Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–437.
- Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–2114. DOI:https://doi.org/10.1056/NEJMoa2034442.
- Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. DOI:https://doi.org/10.1056/NEJMoa2026982.
- Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. DOI:https://doi.org/10.1056/NEJMoa1602252.
- Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–1867. DOI:https://doi.org/10.1056/NEJMoa2112435.
- Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. DOI:https://doi.org/10.1016/S0140-6736(21)00797-2.
- Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. DOI:https://doi.org/10.1056/NEJMoa1915745.
- Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. DOI:https://doi.org/10.1016/S1470-2045(17)30624-1.
- Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treat Rev. 2020;86:102016.
- Coupez D, Hulo P, Touchefeu Y, et al. Pembrolizumab for the treatment of colorectal cancer. Expert Opin Biol Ther. 2020;20(3):219–226. DOI:https://doi.org/10.1080/14712598.2020.1718095.
- Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. 2018;24(21):5198–5205.
- Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. DOI:https://doi.org/10.1056/NEJMoa1910549.
- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. DOI:https://doi.org/10.1056/NEJMoa1809615.
- Cortes J, Cescon DW, Rugo HS, et al., Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265): 1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9.
- Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32(9):1198–1200. DOI:https://doi.org/10.1016/j.annonc.2021.06.014.
- Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12(1):111. DOI:https://doi.org/10.1186/s13045-019-0798-2.
- Goldberg J, Pastorello RG, Vallius T, et al. The immunology of hormone receptor positive breast cancer. Front Immunol. 2021. DOI:https://doi.org/10.3389/fimmu.2021.674192.
- Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. DOI:https://doi.org/10.1038/35021093.
- Denkert C. The immunogenicity of breast cancer—molecular subtypes matter. Ann Oncol. 2014;25(8):1453–1455.
- Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs (online first). Nat Rev Clin Oncol. 2021. DOI:https://doi.org/10.1038/s41571-021-00565-2
- Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes. JAMA Oncol. 2016;2(10):1354.
- Criscitiello C, Esposito A, Trapani D, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016;50:205–207.
- Gruosso T, Gigoux M, Manem VSK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129(4):1785–1800. DOI:https://doi.org/10.1172/JCI96313.
- McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–1469. (80). DOI:https://doi.org/10.1126/science.aaf1490.
- Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. DOI:https://doi.org/10.1016/S1470-2045(20)30445-9.
- Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31(3):387–394. DOI:https://doi.org/10.1016/j.annonc.2019.11.010.
- Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241–250.
- Ding H, Zhao J, Zhang Y, et al. Tumor mutational burden and prognosis across pan-cancers. Ann Oncol. 2018;29:viii16–viii17.
- Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer. JAMA Oncol. 2019;5(8):1205. DOI:https://doi.org/10.1001/jamaoncol.2018.7147.
- Tarantino P, Curigliano G. Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opin Biol Ther. 2019;19(5):383–385.
- Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004. DOI:https://doi.org/10.1016/j.annonc.2021.05.801.
- Tolaney SM, Kalinsky K, Kaklamani VG, et al. eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib/II study. Clin Cancer Res. 2021;27(11):3061–3068. DOI:https://doi.org/10.1158/1078-0432.CCR-20-4726.
- Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. DOI:https://doi.org/10.1016/S1470-2045(19)30689-8.
- Narayan P, Wahby S, Gao JJ, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic tnbc whose tumors express PD-L1. Clin Cancer Res. 2020;26(10):2284–2289. DOI:https://doi.org/10.1158/1078-0432.CCR-19-3545.
- Miles DW, Gligorov J, André F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S1147–S1148.
- https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-me. FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic TNBC. cited 13 Aug 2021 .
- Rugo HS, Cortes J, Cescon DW, et al. LBA16 - KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol. 2021;32(suppl_5):S1283–S1346.
- Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria. Lancet. 2020;396(10257):1090–1100. DOI:https://doi.org/10.1016/S0140-6736(20)31953-X.
- Tarantino P, Gandini S, Trapani D, et al. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;159:103223.
- Clifton GT. Peoples and GE. Immunotherapy as a partner for HER2-directed therapies. Expert Rev. Anticancer Ther. 2021;21(7):739–746.https://doi.org/10.1080/14737140.2021.1894932
- Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–382. DOI:https://doi.org/10.1016/S1470-2045(18)30812-X.
- Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295. DOI:https://doi.org/10.1016/S1470-2045(20)30465-4.
- Hamilton EP, Shapiro CL, Petrylak D, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. San Antonio Breast Cancer Symp. 2020.
- Schmid P, Im S-A, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39(15_suppl): 1023–1023. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.1023.
- Huober J, Barrios CH, Niikura N, et al. VP6-2021: iMpassion050: a phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). Ann Oncol. 2021;32(8):1061–1062. DOI:https://doi.org/10.1016/j.annonc.2021.05.800.
- Rugo HS, Delord J-P, Im S-A, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804–2811. DOI:https://doi.org/10.1158/1078-0432.CCR-17-3452.
- Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–686. DOI:https://doi.org/10.1007/s10549-017-4537-5.
- Tolaney SM, Barroso-Sousa R, Keenan T, et al. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2 -negative metastatic breast cancer. JAMA Oncol. 2020;6(10):1598. DOI:https://doi.org/10.1001/jamaoncol.2020.3524.
- Pérez-García JM, Llombart-Cussac A, Gion M, et al. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): an open-label, multicentre, single-arm, phase trial. Eur J Cancer. 2021;148:382–394.
- Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8(1):e000173. DOI:https://doi.org/10.1136/jitc-2019-000173.
- Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 2020;6(5):676. DOI:https://doi.org/10.1001/jamaoncol.2019.6650.
- Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–1718. DOI:https://doi.org/10.1016/j.annonc.2020.09.004.
- Mittendorf EA, V. PA, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370. DOI:https://doi.org/10.1158/2326-6066.CIR-13-0127.
- Salgado R, Bellizzi AM, Rimm D, et al. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol. 2020;21(11):1399–1401.
- Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. DOI:https://doi.org/10.1016/j.annonc.2020.09.010.
- Rugo HS, Loi S, Adams S, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel–treated advanced triple-negative breast cancer. JNCI J Natl Cancer Inst. 2021;113(12):1733–1743. DOI:https://doi.org/10.1093/jnci/djab108.
- Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for pd-l1 expression in non–small cell lung cancer. JAMA Oncol. 2017;3(8):1051. DOI:https://doi.org/10.1001/jamaoncol.2017.0013.
- Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511. DOI:https://doi.org/10.1016/S1470-2045(20)30754-3.
- FDA approves pembrolizumab for adults and children with TMB-H solid tumors [cited 2021 Sep 20]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors .
- Barroso-Sousa R, Keenan TE, Pernas S, et al. Tumor mutational burden and pten alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26(11):2565–2572. DOI:https://doi.org/10.1158/1078-0432.CCR-19-3507.
- Winer EP, Lipatov O, Im S-A, et al. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. J Clin Oncol. 2020;38(15_suppl): 1013–1013. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.1013.
- Emens LA, Molinero L, Adams S, et al. 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: exploratory analysis of the phase III IMpassion130 trial. Ann Oncol. 2020;31:S360–S361.
- Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent And Profiling Utilization Registry (TAPUR) study. J Clin Oncol. 2021;39(22):2443–2451. DOI:https://doi.org/10.1200/JCO.20.02923.
- Barroso-Sousa R, Trippa L, Lange P, et al. Nimbus: a phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. J Clin Oncol. 2019;37(15_suppl): TPS1115–TPS1115. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS1115.
- O’Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12(5):394–400.
- Loi S, Adams S, Schmid P, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. 2017;28:v608.
- Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab -paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the impassion130 study. JNCI J Natl Cancer Inst. 2021;113(8):1005–1016. DOI:https://doi.org/10.1093/jnci/djab004.
- Wein L, Savas P, Luen SJ, et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol. 2017;7. DOI:https://doi.org/10.3389/fonc.2017.00156.
- Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. DOI:https://doi.org/10.1038/s41571-020-0413-z.
- Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27(2):250–255.
- Loi S, Schmid P, Cortés J, et al. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086. Clin. Res. (Excluding Clin. Trials), American Association for Cancer Research. 2019; LB-225-LB-225.
- Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin Cancer Res. 1999;5(4):839–844.
- Sivapiragasam A, Ashok Kumar P, Sokol ES, et al. Predictive biomarkers for immune checkpoint inhibitors in metastatic breast cancer. Cancer Med. 2021;10(1):53–61. DOI:https://doi.org/10.1002/cam4.3550.
- Dtdt L, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. DOI:https://doi.org/10.1056/NEJMoa1500596.
- Tarantino P, Mazzarella L, Marra A, et al. The evolving paradigm of biomarker actionability: histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev. 2021;94:102169.
- Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):clincanres.4070.2018.
- Conley BA, Staudt L, Takebe N, et al. The exceptional responders initiative: feasibility of a national cancer institute pilot study. JNCI J Natl Cancer Inst. 2021;113(1):27–37. DOI:https://doi.org/10.1093/jnci/djaa061.
- Emens LA, Goldstein LD, Schmid P, et al., The tumor microenvironment (TME) and atezolizumab + nab -paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): iMpassion130. J Clin Oncol. 2021;39(15_suppl): 1006–1006. . https://doi.org/10.1200/JCO.2021.39.15_suppl.1006.
- Han G, Yang G, Hao D, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021;12(1):5606. DOI:https://doi.org/10.1038/s41467-021-25894-9.
- Samstein RM, Krishna C, Ma X, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat. Cancer. 2020;1(12):1188–1203. DOI:https://doi.org/10.1038/s43018-020-00139-8
- Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the impassion130 study. JNCI J Natl Cancer Inst. 2021;113(8):1005–1016.
- Alpuim Costa D, Nobre JG, Batista MV, et al. Human microbiota and breast cancer—is there any relevant link?—a literature review and new horizons toward personalised medicine. Front Microbiol. 2021;12. DOI:https://doi.org/10.3389/fmicb.2021.584332.
- Tzeng A, Sangwan N, Jia M, et al. Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Med. 2021;13(1):60. DOI:https://doi.org/10.1186/s13073-021-00874-2.
- Barroso-Sousa R, Teles LT. Gut microbiome and breast cancer in the era of cancer Immunotherapy. Curr. Breast Cancer Rep. 2019;11(4):272–276.https://doi.org/10.1007/s12609-019-00346-y
- Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. (80). DOI:https://doi.org/10.1126/science.aan3706.
- Elkrief A, Derosa L, Kroemer G, et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30(10):1572–1579. DOI:https://doi.org/10.1093/annonc/mdz206.
- Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602–609. 80. DOI:https://doi.org/10.1126/science.abb5920.
- Waks AG, Stover DG, Guerriero JL, et al. The immune microenvironment in hormone receptor–positive breast cancer before and after preoperative chemotherapy. Clin Cancer Res. 2019;25(15):4644–4655. DOI:https://doi.org/10.1158/1078-0432.CCR-19-0173.
- Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928. DOI:https://doi.org/10.1038/s41591-019-0432-4.
- Li S, Chen J, Sun Z, et al. Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830–850.
- Chen L, Zhimin S, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study. J Clin Oncol. 2021;39(15_suppl): 1007–1007. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.1007.
- Chung HC, Saada-Bouzid E, Muñoz FL, et al. Abstract PS12-07: lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: early results from the multicohort phase 2 LEAP-005 study. Poster Sess. Abstr., American Association for Cancer Research. 2021; S12-07-PS12-07
- Barroso-Sousa R, Keenan TE, Li T, et al. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer. 2021;7(1):110. DOI:https://doi.org/10.1038/s41523-021-00287-9.
- Schmid P, Loirat D, Savas P, et al. Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2019; CT049–CT049. American Association for Cancer Research.
- Schmid P, Salvador Bofill F, Bermejo B, et al. 123MO - BARBICAN: a randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer. Ann Oncol. 2021;32(suppl_5):S407–S446. DOI:https://doi.org/10.1016/j.annonc.2021.08.404.
- Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132. DOI:https://doi.org/10.1001/jamaoncol.2019.1029.
- Domchek SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164. DOI:https://doi.org/10.1016/S1470-2045(20)30324-7.
- Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. DOI:https://doi.org/10.1056/NEJMoa1706450.
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. DOI:https://doi.org/10.1056/NEJMoa1802905.
- Tarantino P, Antonarelli G, Ascione L, et al. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development (online first). Expert Opin Investig Drugs. 2021;1–15. DOI:https://doi.org/10.1080/13543784.2021.1972968
- Kraehenbuehl L, Weng C-H, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways (Online first). Nat Rev Clin Oncol. 2021. DOI:https://doi.org/10.1038/s41571-021-00552-7.
- Hong DS, Schoffski P, Calvo A, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. J Clin Oncol. 2018;36(15_suppl): 3012–3012. DOI:https://doi.org/10.1200/JCO.2018.36.15_suppl.3012.
- Curigliano G, Gelderblom H, Mach N, et al. Phase I/Ib clinical Trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 2021;27(13):3620–3629. doi:https://doi.org/10.1158/1078-0432.CCR-20-4746
- Yap TA, Burris HA, Kummar S, et al. ICONIC: biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 ± nivolumab (nivo) in patients (pts) with advanced cancers. J Clin Oncol. 2018;36(15_suppl): 3000–3000. DOI:https://doi.org/10.1200/JCO.2018.36.15_suppl.3000.
- Lipson EJ, Tawbi -HA-H, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15_suppl): 9503–9503. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.9503.
- Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38(15_suppl): 9503–9503. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.9503.
- Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–475. DOI:https://doi.org/10.1038/nature23465.
- Rugo HS, Kabos P, Beck JT, et al. A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751. Interim result. J. Clin. Oncol. 2020;38(15_suppl): 1051–1051. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.1051
- Blank CU, Haanen JB, Ribas A, et al. The “cancer immunogram” Visualizing the state of cancer–immune system interactions may spur personalized therapy. Science. 2016;352(6286):658–660. 80. DOI:https://doi.org/10.1126/science.aaf2834.
- Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6(7):703–713.
- Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30(6):998–1004. DOI:https://doi.org/10.1093/annonc/mdz108.
- Wang X, Wang L, Bu H, et al. How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies. Npj Breast Cancer. 2021;7(1):61. DOI:https://doi.org/10.1038/s41523-021-00268-y.
- Groot CA U-D, Heine R, Krol M, et al. Unequal access to newly registered cancer drugs leads to potential loss of life-years in europe. Cancers (Basel). 2020;12(8):2313.
- Trapani D, Yves Douillard J, Winer EP, et al. The global landscape of treatment standards for breast cancer. J Natl Cancer Inst. 2021;113(9):1143–1155.
- Anders CK, LeBoeuf NR, Bashoura L, et al. What’s the price? toxicities of targeted therapies in breast cancer care. Am Soc Clin Oncol Educ B. 2020;40(40):55–70. DOI:https://doi.org/10.1200/EDBK_279465.